Last reviewed · How we verify
Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
Docetaxel + Carboplatin + Trastuzumab + Pertuzumab is a Combination chemotherapy with HER2-targeted monoclonal antibodies Small molecule drug developed by Henan Cancer Hospital. It is currently in Phase 3 development for HER2-positive breast cancer (metastatic or locally advanced), HER2-positive gastric cancer. Also known as: TCbHP regimen group.
This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit HER2-driven cancer cell growth and survival through multiple mechanisms.
This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit HER2-driven cancer cell growth and survival through multiple mechanisms. Used for HER2-positive breast cancer (metastatic or locally advanced), HER2-positive gastric cancer.
At a glance
| Generic name | Docetaxel + Carboplatin + Trastuzumab + Pertuzumab |
|---|---|
| Also known as | TCbHP regimen group |
| Sponsor | Henan Cancer Hospital |
| Drug class | Combination chemotherapy with HER2-targeted monoclonal antibodies |
| Target | HER2 (trastuzumab and pertuzumab); microtubules (docetaxel); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel stabilizes microtubules to disrupt cell division, while carboplatin causes DNA damage. Trastuzumab and pertuzumab are monoclonal antibodies that target HER2 on cancer cell surfaces, blocking growth signaling and recruiting immune-mediated cell death. Together, they provide synergistic anti-tumor activity in HER2-positive cancers.
Approved indications
- HER2-positive breast cancer (metastatic or locally advanced)
- HER2-positive gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Fatigue
- Cardiotoxicity (left ventricular dysfunction)
- Hypersensitivity reactions
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (PHASE2)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
- Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer (NA)
- EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab CI brief — competitive landscape report
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI
Frequently asked questions about Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
What is Docetaxel + Carboplatin + Trastuzumab + Pertuzumab?
How does Docetaxel + Carboplatin + Trastuzumab + Pertuzumab work?
What is Docetaxel + Carboplatin + Trastuzumab + Pertuzumab used for?
Who makes Docetaxel + Carboplatin + Trastuzumab + Pertuzumab?
Is Docetaxel + Carboplatin + Trastuzumab + Pertuzumab also known as anything else?
What drug class is Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in?
What development phase is Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in?
What are the side effects of Docetaxel + Carboplatin + Trastuzumab + Pertuzumab?
What does Docetaxel + Carboplatin + Trastuzumab + Pertuzumab target?
Related
- Drug class: All Combination chemotherapy with HER2-targeted monoclonal antibodies drugs
- Target: All drugs targeting HER2 (trastuzumab and pertuzumab); microtubules (docetaxel); DNA (carboplatin)
- Manufacturer: Henan Cancer Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2-positive breast cancer (metastatic or locally advanced)
- Indication: Drugs for HER2-positive gastric cancer
- Also known as: TCbHP regimen group
- Compare: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab vs similar drugs
- Pricing: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab cost, discount & access